Építés alatt – nem éles oldal
Belépés
Leállítva3. fázis

Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

A legfontosabb adatok

Ki végzi
Fred Hutchinson Cancer Center
Hol
Ann Arbor, Baltimore, Boston, Burlington, Charleston, Cincinnati, Cleveland, Columbus, Denver, Detroit, Durham, Madison, Murray, Nashville, Pittsburgh, Seattle, St Louis, The Bronx és Winston-Salem (Egyesült Államok)Mind a 20 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
3. fázis
Résztvevők
205 fő vett részt
Kezdés
2021. jún. 29.
Befejezés
2025. ápr. 8.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • IV Ganciclovir
  • Normal saline
A regiszteradat frissítve
2026. október 20.
Miért állt le
due to increased mortality and futility analyses

Ki vehet részt

Életkor
18 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject/next of kin informed consent
  • Age > 18 years
  • CMV IgG seropositive by lateral flow assay (LFA) or standard serologic methods
  • Receiving care in an ICU
  • Acute respiratory failure as defined in Section 4.1.1
  • Expected to require respiratory support for at least 2 more days after randomization
  • Infection confirmed or suspected by the treating clinician and felt to be the source of acute respiratory failure (Respiratory failure associated with infection confers at least 2 SOFA points above assumed baseline SOFA score of 0, thereby meeting Sepsis-3 definition)

Ki nem vehet részt

  • Known or suspected immunosuppression, including:; HIV+ (i.e. prior positive test or clinical signs of suspicion of HIV/AIDS; a negative HIV test is not required for enrollment); stem cell transplantation:; within 6 months after autologous transplantation or; within 1 years after allogeneic transplantation (regardless of immunosuppression); greater than 1 year of allogeneic transplantation if still taking systemic immunosuppression or prophylactic antibiotics (e.g. for chronic graft versus host disease) Note: if details of stem cell transplantation are unknown, patients who do not take systemic immunosuppression and do not take anti-infective prophylaxis are acceptable for enrollment and randomization; solid organ transplantation with receipt of systemic immunosuppression (any time); cytotoxic anti-cancer chemotherapy within the past three months (Note: next-of-kin estimate is acceptable); congenital immunodeficiency requiring antimicrobial prophylaxis (e.g. TMP-SMX, dapsone, antifungal drugs, intravenous immunoglobulin); receipt of one or more of the following in the indicated time period (see Appendix C):; within 6 months: alemtuzumab, antithymocyte/antilymphocyte antibodies, or other immunosuppressive drugs associated with CMV reactivation Note: if no information on these agents is available in the history and no direct or indirect evidence exists from the history that any condition exists that requires treatment with these agents (based on the investigator's assessment), the subject may be enrolled. For all drug information, next-of-kin estimates are acceptable. See Appendix C for commonly prescribed immunosuppressive agents. Information on the use of biologics with moderate immunosuppressive effect but no known effect on CMV are permitted and will be recorded in the CRFs
  • Use of anti-CMV drugs (cidofovir, letermovir, foscarnet, valganciclovir, ganciclovir) within seven (7) days of patient randomization
  • Currently enrolled in an interventional trial of an investigational therapeutic agent known or suspected to have anti-CMV activity or to be associated with significant known hematologic toxicity (prior approval required)
  • Patients with severe (requiring home oxygen) pre-existing interstitial lung disease
  • Allergy to ganciclovir
  • Absolute neutrophil count < 1,000/mm3 (if no ANC value is available, the WBC must be > 2500/mm3)
  • Pregnant or breastfeeding (either currently or expected within one month). Note: for women of childbearing age (18-60 years, unless documentation of surgical sterilization [hysterectomy, tubal ligation, oophorectomy]), if a pregnancy test has not been done as part of initial ICU admission work-up, it will be ordered stat and documented to be negative before randomization. Both urine and blood tests are acceptable
  • Expected to survive < 72 hours (in the opinion of the investigator)
  • Has been hospitalized for > 120 hours (subjects who are transferred from a chronic care ward, such as a rehabilitation unit, with an acute event are acceptable)
  • At baseline patients who have both a tracheostomy, and have been on continuous 24-hour chronic mechanical ventilation
  • Patients with Child Class C Cirrhosis
  • Incarcerated

Helyszínek itt: Egyesült Államok

  • University of MichiganAnn Arbor, Egyesült Államok
  • Johns Hopkins UniversityBaltimore, Egyesült Államok
  • Brigham & Women's HospitalBoston, Egyesült Államok
  • University of Vermont College of MedicineBurlington, Egyesült Államok
  • Medical College of South CarolinaCharleston, Egyesült Államok
  • University of CincinnatiCincinnati, Egyesült Államok
  • The Cleveland Clinic FoundationCleveland, Egyesült Államok
  • Ohio State University Medical CenterColumbus, Egyesült Államok
  • University of Colorado DenverDenver, Egyesült Államok
  • Henry Ford HospitalDetroit, Egyesült Államok
  • Duke UniversityDurham, Egyesült Államok
  • University of Wisconsin School of Medicine & Public HealthMadison, Egyesült Államok
  • Intermountain Medical CenterMurray, Egyesült Államok
  • Vanderbilt UniversityNashville, Egyesült Államok
  • University of Pittsburgh Medical CenterPittsburgh, Egyesült Államok
  • Harborview Medical CenterSeattle, Egyesült Államok
  • University of Washington Medical CenterSeattle, Egyesült Államok
  • Washington UniversitySt Louis, Egyesült Államok
  • Montefioure Medical CenterThe Bronx, Egyesült Államok
  • Wakeforest University, School of MedicineWinston-Salem, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a phase 3 study designed to evaluate whether the administration of ganciclovir increases ventilator-free days in immunocompetent patients with sepsis associated acute respiratory failure. Our hypothesis is that IV ganciclovir administered early in critical illness will effectively suppress CMV reactivation in CMV seropositive adults with sepsis-associated acute respiratory failure thereby leading to improved clinical outcomes

A vizsgálat 2 csoportja

  • IV GanciclovirA vizsgált kezelés

    5mg/kg IV twice daily for 5 days, then followed by IV ganciclovir once daily until hospital discharge

  • PlaceboPlacebo, összehasonlításként

    normal saline IV twice daily for 5 days, then followed by IV normal saline once daily until hospital discharge

    Kezelés: Normal saline

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. október 20.